Innoveren Scientific Inc. (IVRN)
OTCMKTS: IVRN · Delayed Price · USD
0.0200
0.00 (0.00%)
Apr 17, 2024, 12:00 AM EDT - Market open
Company Description
Innoveren Scientific Inc., a medical bioscience company that develops technology in regenerative medicine for limb salvage.
It is also developing immunotherapies for ovarian cancer, pancreatic cancer, and mesothelioma. The company was formerly known as H-CYTE, Inc. and changed its name to Innoveren Scientific Inc. in July 2023.
The company is headquartered in Tampa, Florida.
Innoveren Scientific Inc.
| Country | United States |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
Contact Details
Address: 151 W4th St, Ste 223 Cincinnati, Ohio 45202 United States | |
| Phone | 844-633-6839 |
Stock Details
| Ticker Symbol | IVRN |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001591165 |
| Employer ID | 46-3312262 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Michael W. Yurkowsky | Chief Executive Officer and Director |
| Jeremy D. Daniel | Chief Financial Officer |
| Dr. Tanya Rhodes Ph.D. | Chief Scientific Officer |
| Jeffery Wright CPA, CPA | Controller and Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 2, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Apr 1, 2024 | 8-K | Current Report |
| Mar 6, 2024 | 8-K | Current Report |
| Feb 28, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 6, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Dec 21, 2023 | 8-K | Current Report |
| Nov 15, 2023 | 10-Q | Quarterly Report |
| Nov 15, 2023 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Nov 15, 2023 | 10-Q | Quarterly Report |